Operaciones Aytu BioScience, Inc. - AYTU CFD
Agregar a Favoritos- Resumen
- Datos históricos
- Eventos
- Cuenta de resultados
- Balance de situación
- Flujo de caja
- Propiedad
Condiciones de trading
| Diferencial | 0.152 | ||||||||
|
Tarifa nocturna posición alcista
Long position overnight fee
Ir a la plataforma | -0.025457% | ||||||||
|
Tarifa nocturna posición bajista
Short position overnight fee
Ir a la plataforma | 0.003235% | ||||||||
| Horario tarifa nocturna | 21:00 (UTC) | ||||||||
| Cantidad comercializada mínima | 0.01 | ||||||||
| Divisa | USD | ||||||||
| Margen | 20% | ||||||||
| Mercado de valores | United States of America | ||||||||
| Comisión por operación | 0% |
*Information provided by Capital.com
Aytu Biopharma Inc ESG Risk Ratings
High Medium Low Negligible
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
Estadísticas clave
| Cierre previo* | 1.509 |
| Abrir* | 1.469 |
| Cambio de 1 año* | 173.05% |
| Rango del día* | 1.469 - 1.608 |
| Rango de 52 semanas | 1.40-16.19 |
| Volumen medio (10 días) | 59.71K |
| Volumen medio (3 meses) | 1.67M |
| Capitalización de mercado | 5.93M |
| Ratio P/E | -100.00K |
| Acciones en circulación | 3.78M |
| Ingresos | 104.12M |
| EPS | -206.58 |
| Dividendo (Rendimiento %) | N/A |
| Beta | -0.38 |
| Próxima fecha de resultados | Sep 25, 2023 |
"Todos los datos son proporcionados por Refinitiv, excepto los datos marcados con un asterisco, que son *datos proporcionados por Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Cierre | Change | Change (%) | Apertura | High | Low |
|---|---|---|---|---|---|---|
| Jun 9, 2023 | 1.529 | 0.050 | 3.38% | 1.479 | 1.608 | 1.469 |
| Jun 8, 2023 | 1.509 | 0.040 | 2.72% | 1.469 | 1.529 | 1.469 |
| Jun 7, 2023 | 1.539 | -0.078 | -4.82% | 1.617 | 1.618 | 1.479 |
| Jun 6, 2023 | 1.568 | -0.078 | -4.74% | 1.646 | 1.648 | 1.568 |
| Jun 5, 2023 | 1.687 | -0.039 | -2.26% | 1.726 | 1.726 | 1.637 |
| Jun 2, 2023 | 1.736 | 0.139 | 8.70% | 1.597 | 1.736 | 1.587 |
| Jun 1, 2023 | 1.647 | 0.060 | 3.78% | 1.587 | 1.667 | 1.568 |
| May 31, 2023 | 1.618 | -0.038 | -2.29% | 1.656 | 1.657 | 1.568 |
| May 30, 2023 | 1.618 | -0.078 | -4.60% | 1.696 | 1.697 | 1.587 |
| May 26, 2023 | 1.627 | 0.000 | 0.00% | 1.627 | 1.805 | 1.617 |
| May 25, 2023 | 1.618 | -0.147 | -8.33% | 1.765 | 1.766 | 1.558 |
| May 24, 2023 | 1.746 | -0.029 | -1.63% | 1.775 | 1.815 | 1.696 |
| May 23, 2023 | 1.765 | -0.009 | -0.51% | 1.774 | 1.904 | 1.765 |
| May 22, 2023 | 1.874 | 0.020 | 1.08% | 1.854 | 1.934 | 1.824 |
| May 19, 2023 | 1.844 | 0.020 | 1.10% | 1.824 | 1.934 | 1.795 |
| May 18, 2023 | 1.835 | 0.020 | 1.10% | 1.815 | 1.854 | 1.775 |
| May 17, 2023 | 1.736 | 0.090 | 5.47% | 1.646 | 1.746 | 1.607 |
| May 16, 2023 | 1.677 | 0.001 | 0.06% | 1.676 | 1.795 | 1.666 |
| May 15, 2023 | 1.726 | 0.011 | 0.64% | 1.715 | 1.805 | 1.697 |
| May 12, 2023 | 1.776 | -0.246 | -12.17% | 2.022 | 2.022 | 1.726 |
Aytu BioScience, Inc. Events
| Hora (UTC) (UTC) | País | Evento |
|---|---|---|
| Monday, September 25, 2023 | ||
| Hora (UTC) (UTC) 20:00 | País US
| Evento Q4 2023 Aytu Biopharma Inc Earnings Release Q4 2023 Aytu Biopharma Inc Earnings ReleaseForecast -Previous - |
| Monday, November 13, 2023 | ||
| Hora (UTC) (UTC) 21:00 | País US
| Evento Q1 2024 Aytu Biopharma Inc Earnings Release Q1 2024 Aytu Biopharma Inc Earnings ReleaseForecast -Previous - |
- Anual
- Trimestral
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Ingresos totales | 96.669 | 65.632 | 27.6321 | 7.32036 | 3.66012 |
| Ingresos | 96.669 | 65.632 | 27.6321 | 7.32036 | 3.66012 |
| Coste de los ingresos, total | 44.386 | 36.432 | 7.55303 | 2.20204 | 2.05054 |
| Beneficio bruto | 52.283 | 29.2 | 20.0791 | 5.11832 | 1.60958 |
| Gastos totales de explotación | 208.061 | 126.071 | 38.6481 | 33.9975 | 17.0825 |
| Gastos de venta/general/administración Gastos, total | 69.88 | 55.808 | 34.8024 | 19.2396 | 17.7325 |
| Investigación y desarrollo | 14.439 | 5.623 | 1.72142 | 0.58907 | 0.1676 |
| Depreciation / Amortization | 4.067 | 6.009 | 4.49047 | 2.13626 | 1.55371 |
| Gastos (ingresos) extraordinarios | 75.289 | 22.199 | -9.91925 | 9.83055 | -4.42185 |
| Ingresos de explotación | -111.392 | -60.439 | -11.016 | -26.6772 | -13.4224 |
| Ingresos por intereses (gastos), netos No operativos | -0.862 | -2.05 | -2.60466 | -0.45472 | 3.2345 |
| Ingresos netos antes de impuestos | -110.283 | -58.03 | -13.6207 | -27.1319 | -10.1879 |
| Ingresos netos después de impuestos | -110.173 | -58.289 | -13.6207 | -27.1319 | -10.1879 |
| Beneficio neto antes de partidas extra. Elementos | -110.173 | -58.289 | -13.6207 | -27.1319 | -10.1879 |
| Ingresos netos | -110.173 | -58.289 | -13.6207 | -27.1319 | -10.1879 |
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -110.173 | -58.289 | -13.6207 | -27.1319 | -10.1879 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -110.173 | -58.289 | -13.6207 | -27.1319 | -10.1879 |
| Beneficio neto diluido | -110.173 | -58.289 | -13.6207 | -27.1319 | -10.1879 |
| Promedio ponderado de acciones diluidas | 0.07349 | 0.83733 | 0.22596 | 0.03897 | 0.00333 |
| BPA diluido sin partidas extraordinarias | -1499.08 | -69.6126 | -60.2791 | -696.182 | -3061.23 |
| Dividends per Share - Common Stock Primary Issue | |||||
| BPA normalizado diluido | -833.202 | -52.3801 | -104.177 | -443.938 | -4389.91 |
| Total de partidas extraordinarias | 0 | ||||
| Otros, netos | 1.971 | 4.459 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Ingresos totales | 22.733 | 26.279 | 27.655 | 27.448 | 24.199 |
| Ingresos | 22.733 | 26.279 | 27.655 | 27.448 | 24.199 |
| Coste de los ingresos, total | 9.99 | 8.986 | 9.623 | 12.606 | 11.513 |
| Beneficio bruto | 12.743 | 17.293 | 18.032 | 14.842 | 12.686 |
| Gastos totales de explotación | 31.291 | 33.072 | 29.308 | 45.361 | 78.685 |
| Gastos de venta/general/administración Gastos, total | 19.981 | 18.578 | 17.424 | 17.396 | 17.358 |
| Investigación y desarrollo | 0.856 | 1.71 | 1.064 | 3.697 | 3.726 |
| Depreciation / Amortization | 1.198 | 1.198 | 1.197 | 0.853 | 1.061 |
| Gastos (ingresos) extraordinarios | 0 | 2.6 | 10.809 | 45.027 | |
| Ingresos de explotación | -8.558 | -6.793 | -1.653 | -17.913 | -54.486 |
| Ingresos por intereses (gastos), netos No operativos | 1.358 | 0.1 | 1.08 | -0.787 | -0.055 |
| Otros, netos | -0.128 | 0.999 | 1.468 | ||
| Ingresos netos antes de impuestos | -7.2 | -6.693 | -0.701 | -17.701 | -53.073 |
| Ingresos netos después de impuestos | -7.2 | -6.693 | -0.701 | -17.701 | -53.073 |
| Beneficio neto antes de partidas extra. Elementos | -7.2 | -6.693 | -0.701 | -17.701 | -53.073 |
| Ingresos netos | -7.2 | -6.693 | -0.701 | -17.701 | -53.073 |
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -7.2 | -6.693 | -0.701 | -17.701 | -53.073 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -7.2 | -6.693 | -0.701 | -17.701 | -53.073 |
| Beneficio neto diluido | -7.2 | -6.693 | -0.701 | -17.701 | -53.073 |
| Promedio ponderado de acciones diluidas | 3.72678 | 3.1103 | 0.1259 | 0.08989 | 1.48449 |
| BPA diluido sin partidas extraordinarias | -1.93196 | -2.15188 | -5.56812 | -196.925 | -35.7516 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| BPA normalizado diluido | -1.93196 | -1.31595 | -5.56812 | -76.6739 | -5.42003 |
| Other Operating Expenses, Total | -0.734 |
- Anual
- Trimestral
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Activo Corriente | 59.929 | 105.234 | 75.4226 | 15.4329 | 9.47029 |
| Efectivo e inversiones a corto plazo | 19.36 | 49.649 | 48.0817 | 11.0442 | 7.01253 |
| Efectivo y Equivalentes | 19.36 | 49.649 | 48.0817 | 11.0442 | 7.01253 |
| Inversiones a corto plazo | |||||
| Total deudores, neto | 21.712 | 28.176 | 5.63272 | 1.74079 | 0.57878 |
| Accounts Receivable - Trade, Net | 21.712 | 28.176 | 5.63272 | 1.74079 | 0.57878 |
| Total Inventory | 10.849 | 16.339 | 9.99944 | 1.44007 | 1.33897 |
| Prepaid Expenses | 7.375 | 9.78 | 5.71509 | 0.95778 | 0.44001 |
| Total Assets | 137.623 | 265.668 | 153.293 | 34.7214 | 21.0601 |
| Property/Plant/Equipment, Total - Net | 6.296 | 8.703 | 0.89261 | 0.20373 | 0.21868 |
| Goodwill, Net | 0 | 65.802 | 28.0904 | 0 | |
| Intangibles, Net | 70.632 | 85.464 | 48.8546 | 19.0826 | 11.366 |
| Other Long Term Assets, Total | 0.766 | 0.465 | 0.03298 | 0.0022 | 0.00509 |
| Total Current Liabilities | 64.442 | 109.438 | 28.7634 | 5.37258 | 3.39478 |
| Payable/Accrued | 9.468 | 8.689 | 0.959 | ||
| Accrued Expenses | 35.946 | 49.485 | 11.1046 | 1.99724 | 0.72656 |
| Notes Payable/Short Term Debt | 3.813 | 7.934 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 4.132 | 7.407 | 4.87523 | 1.07807 | 0.54855 |
| Total Liabilities | 91.531 | 128.1 | 58.2778 | 27.6336 | 7.63559 |
| Total Long Term Debt | 14.279 | 0.18 | 0 | 0 | 0 |
| Other Liabilities, Total | 12.81 | 18.482 | 29.5145 | 22.261 | 4.24081 |
| Total Equity | 46.092 | 137.568 | 95.0153 | 7.08782 | 13.4245 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0.00036 | 0 |
| Common Stock | 0.004 | 0.003 | 0.00126 | 0.00175 | 0.00018 |
| Additional Paid-In Capital | 334.56 | 315.864 | 215.024 | 113.475 | 92.6819 |
| Retained Earnings (Accumulated Deficit) | -288.472 | -178.299 | -120.01 | -106.39 | -79.2576 |
| Total Liabilities & Shareholders’ Equity | 137.623 | 265.668 | 153.293 | 34.7214 | 21.0601 |
| Total Common Shares Outstanding | 1.92894 | 1.37452 | 0.62919 | 0.08769 | 0.00897 |
| Other Current Assets, Total | 0.633 | 1.29 | 5.9936 | 0.25 | 0.1 |
| Accounts Payable | 10.987 | 19.255 | 11.8246 | 2.29727 | 2.11967 |
| Property/Plant/Equipment, Total - Gross | 8.717 | 9.715 | 1.37661 | 0.59973 | 0.75868 |
| Accumulated Depreciation, Total | -2.421 | -1.012 | -0.484 | -0.396 | -0.54 |
| Total Preferred Shares Outstanding | 0 | 0 | 3.59498 | ||
| Current Port. of LT Debt/Capital Leases | 0.096 | 16.668 | 0 | ||
| Capital Lease Obligations | 0.084 | 0.18 | 0 | ||
| Long Term Debt | 14.195 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Activo Corriente | 78.465 | 70.611 | 74.415 | 59.929 | 77.947 |
| Efectivo e inversiones a corto plazo | 19.179 | 19.501 | 23.811 | 19.36 | 27.613 |
| Efectivo y Equivalentes | 19.179 | 19.501 | 23.811 | 19.36 | 27.613 |
| Total deudores, neto | 34.043 | 25.547 | 27.924 | 21.712 | 27.613 |
| Accounts Receivable - Trade, Net | 34.043 | 25.547 | 27.924 | 21.712 | 27.613 |
| Total Inventory | 13.637 | 12.95 | 12.871 | 10.849 | 13.891 |
| Prepaid Expenses | 10.429 | 11.989 | 9.024 | 7.375 | 7.942 |
| Other Current Assets, Total | 1.177 | 0.624 | 0.785 | 0.633 | 0.888 |
| Total Assets | 147.216 | 141.436 | 150 | 137.623 | 168.826 |
| Property/Plant/Equipment, Total - Net | 4.395 | 5.019 | 5.648 | 6.296 | 7.04 |
| Property/Plant/Equipment, Total - Gross | 7.779 | 8.083 | 8.384 | 8.717 | 8.78 |
| Accumulated Depreciation, Total | -3.384 | -3.064 | -2.736 | -2.421 | -1.74 |
| Goodwill, Net | 0 | 8.637 | |||
| Intangibles, Net | 63.464 | 64.985 | 69.108 | 70.632 | 74.428 |
| Other Long Term Assets, Total | 0.892 | 0.821 | 0.829 | 0.766 | 0.774 |
| Total Current Liabilities | 85.416 | 67.15 | 73.204 | 64.442 | 80.36 |
| Accounts Payable | 14.673 | 10.58 | 14.667 | 10.987 | 11.13 |
| Payable/Accrued | 10.287 | 9.137 | 8.08 | 9.468 | 12.058 |
| Accrued Expenses | 40.55 | 33.326 | 34.603 | 35.946 | 47.873 |
| Notes Payable/Short Term Debt | 10.403 | 7.429 | 8.087 | 3.813 | 3.385 |
| Current Port. of LT Debt/Capital Leases | 3.305 | 0.09 | 0.925 | 0.096 | 0.1 |
| Other Current Liabilities, Total | 6.198 | 6.588 | 6.842 | 4.132 | 5.814 |
| Total Liabilities | 106.304 | 95.619 | 96.094 | 91.531 | 107.682 |
| Total Long Term Debt | 11.386 | 14.533 | 13.56 | 14.279 | 14.167 |
| Long Term Debt | 11.371 | 14.494 | 13.498 | 14.195 | 14.061 |
| Capital Lease Obligations | 0.015 | 0.039 | 0.062 | 0.084 | 0.106 |
| Other Liabilities, Total | 9.502 | 13.936 | 9.33 | 12.81 | 13.155 |
| Total Equity | 40.912 | 45.817 | 53.906 | 46.092 | 61.144 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.00038 | 0.00034 | 0.006 | 0.004 | 0.003 |
| Additional Paid-In Capital | 342.584 | 340.289 | 345.253 | 334.56 | 331.912 |
| Retained Earnings (Accumulated Deficit) | -301.672 | -294.472 | -291.353 | -288.472 | -270.771 |
| Total Liabilities & Shareholders’ Equity | 147.216 | 141.436 | 150 | 137.623 | 168.826 |
| Total Common Shares Outstanding | 3.77951 | 3.38315 | 3.12147 | 1.92894 | 1.6678 |
| Total Preferred Shares Outstanding | |||||
| Other Equity, Total | -0.00038 | -0.00034 |
- Anual
- Trimestral
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Ingresos netos/Línea de salida | -110.173 | -58.289 | -13.6207 | -27.1319 | -10.1879 |
| Efectivo de actividades de explotación | -28.823 | -25.964 | -28.3739 | -13.8314 | -15.9403 |
| Efectivo de actividades de explotación | 10.251 | 9.201 | 6.24583 | 2.72707 | 2.59127 |
| Deferred Taxes | |||||
| Partidas no monetarias | 81.962 | 21.443 | -8.38913 | 10.7837 | -7.62492 |
| Cambios en el capital circulante | -10.863 | 1.681 | -12.6099 | -0.2102 | -0.71881 |
| Efectivo de actividades de inversión | -3.248 | -2.782 | -5.65577 | -1.06199 | -0.48429 |
| Gastos de capital | -2.341 | 0 | -0.05985 | -0.07471 | |
| Otras partidas de flujo de caja de inversión, total | -3.248 | -0.441 | -5.65577 | -1.00214 | -0.40959 |
| Efectivo procedente de actividades de financiación | 1.53 | 30.314 | 71.0687 | 19.0751 | 22.6596 |
| Elementos de flujo de caja de financiación | -4.942 | -10.996 | -5.40415 | -1.47996 | -2.75752 |
| Emisión (retiro) de acciones, neto | 11.694 | 45.051 | 92.7217 | 15.555 | 25.4171 |
| Emisión (amortización) de deuda, neta | -5.222 | -3.741 | -16.2488 | 5 | |
| Variación neta de la tesorería | -30.541 | 1.568 | 37.0391 | 4.1817 | 6.23499 |
| Intereses pagados en efectivo | 3.148 | 1.249 | 1.04028 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -14.594 | -7.394 | -2.881 | -110.173 | -92.472 |
| Cash From Operating Activities | -14.494 | -11.588 | -9.148 | -28.823 | -21.728 |
| Cash From Operating Activities | 6.699 | 4.505 | 2.328 | 10.251 | 8.005 |
| Non-Cash Items | 1.658 | 3.846 | 1.488 | 81.962 | 67.39 |
| Cash Interest Paid | 2.861 | 2.021 | 0.565 | 3.148 | 3.08 |
| Changes in Working Capital | -8.257 | -12.545 | -10.083 | -10.863 | -4.651 |
| Cash From Investing Activities | 0.038 | 0.037 | 0.042 | -3.248 | -3.207 |
| Other Investing Cash Flow Items, Total | 0.038 | 0.037 | 0.042 | -3.248 | -3.207 |
| Cash From Financing Activities | 14.275 | 11.692 | 13.557 | 1.53 | 2.647 |
| Financing Cash Flow Items | -5.254 | -3.497 | -1.107 | -4.942 | -4.429 |
| Issuance (Retirement) of Stock, Net | 13.012 | 11.573 | 10.416 | 11.694 | 12.7 |
| Issuance (Retirement) of Debt, Net | 6.517 | 3.616 | 4.248 | -5.222 | -5.624 |
| Net Change in Cash | -0.181 | 0.141 | 4.451 | -30.541 | -22.288 |
| Capital Expenditures |
| Nombre del Inversor | Tipo de inversor | Porcentaje pendiente | Acciones en propiedad | Cambio de acciones | Fechas de holding | Índice de rotación |
|---|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | Hedge Fund | 7.1847 | 271595 | 0 | 2023-05-26 | LOW |
| Alyeska Investment Group, L.P. | Hedge Fund | 1.984 | 75000 | 0 | 2023-03-31 | |
| Brooke (Christopher) | Individual Investor | 1.5438 | 58357 | 58357 | 2022-11-15 | |
| Disbrow (Joshua R.) | Individual Investor | 1.5235 | 57591 | -3 | 2023-03-24 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 1.3127 | 49623 | -57416 | 2023-03-31 | HIGH |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 1.2503 | 47263 | 4379 | 2023-03-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.6365 | 24059 | -1 | 2023-03-31 | LOW |
| Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 0.5962 | 22537 | 2640 | 2023-03-31 | MED |
| Commonwealth Financial Network | Investment Advisor | 0.4137 | 15637 | 159 | 2023-03-31 | LOW |
| PGIM Quantitative Solutions LLC | Investment Advisor | 0.375 | 14176 | 5198 | 2023-03-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.3185 | 12039 | -2 | 2023-03-31 | LOW |
| Oki (Mark K) | Individual Investor | 0.2513 | 9500 | 0 | 2023-03-24 | LOW |
| Pyszczymuka (Greg) | Individual Investor | 0.2408 | 9103 | 5000 | 2022-12-19 | |
| Cantrell (Gary V.) | Individual Investor | 0.217 | 8204 | -2000 | 2022-12-21 | |
| Dockery (Carl C) | Individual Investor | 0.2157 | 8152 | -2 | 2023-03-24 | LOW |
| Liu (Vivian H) | Individual Investor | 0.1805 | 6825 | 0 | 2023-03-24 | HIGH |
| Ronald Blue Trust, Inc. | Investment Advisor | 0.1476 | 5579 | 5300 | 2023-03-31 | LOW |
| UBS Financial Services, Inc. | Investment Advisor | 0.1395 | 5273 | 5012 | 2023-03-31 | LOW |
| Tower Research Capital LLC | Hedge Fund | 0.0457 | 1726 | 113 | 2023-03-31 | HIGH |
| Morgan Stanley & Co. LLC | Research Firm | 0.0228 | 861 | 0 | 2023-03-31 | MED |
¿Por qué operar con Capital.com? Nuestros números hablan por nosotros
Capital.com Group535K+
Traders
87K+
Clientes activos mensualmente
$113M+
Volumen mensual de inversión
$64M+
Retiros por mes
Calculadora de trading
Calcula tus P&L hipotéticas en el supuesto de haber abierto una operación con CFD en una fecha determinada (selecciona una fecha) y haberla cerrado en otra fecha (selecciona una fecha).
Comisión de la operación
0
- 1:1
Apalancamiento
1:1
- 20
- 100
- 500
- 1000
- 10000
Inversión
Tamaño de la operación (Apalancamiento x Inversión)
Apertura
Cierre
En corto En largo
Aytu BioScience, Inc. Company profile
Sobre Aytu Biopharma Inc
Aytu Biopharma, Inc, anteriormente Aytu BioScience, Inc, es una empresa farmacéutica especializada. La empresa comercializa una cartera de productos de prescripción dirigidos a los mercados de atención primaria y pediátrica. Los principales productos de prescripción de la empresa tratan el trastorno por déficit de atención e hiperactividad (TDAH) y otras afecciones pediátricas comunes. Comercializa los productos para el TDAH Adzenys XR-ODT (anfetamina) en comprimidos de liberación prolongada por vía oral, Cotempla XR-ODT (metilfenidato) en comprimidos de liberación prolongada por vía oral y Adzenys-ER (anfetamina) en suspensión oral de liberación prolongada. Otros productos pediátricos de la empresa son Karbinal ER (maleato de carbinoxamina), una suspensión de carbinoxamina (antihistamínico) de liberación prolongada indicada para tratar numerosas afecciones alérgicas, y Poly-Vi-Flor y Tri-Vi-Flor, dos líneas complementarias de productos vitamínicos de prescripción basados en el flúor que contienen combinaciones de flúor y vitaminas en fórmulas para lactantes y niños con deficiencia de flúor.
El precio actual de la acción Aytu BioScience, Inc. en tiempo real es 1.519 USD. El gráfico de la acción permite a los inversores comprender mejor el rendimiento y el precio de la acción y tomar decisiones informadas al negociar acciones y CFD.
Descubra más acciones con gráficos, datos vitales y actualizaciones de precios en tiempo real: Steel Dynamics, Inc., Otter Tail, Central Garden&Pet, Waters, ADMA Biologics, Inc. y City Holding. Para obtener más información, consulte los perfiles de las empresas en Capital.com.
| Industry: | Pharmaceuticals (NEC) |
373 Inverness Pkwy Ste 206
80112
Cuenta de resultados
- Annual
- Quarterly
A la gente también le interesa
¿Aún estás buscando un bróker de confianza?
Únete a más de 535.000 traders de todo el mundo que eligen operar con Capital.com